Led by Dr. Ding, one of the earliest practitioners in peptide drug research in China, our scientific team is dedicated to in-depth exploration in areas such as metabolic diseases, antiviral and antibacterial solutions, immunological disorders, and anticancer therapeutics. We have successfully completed or are currently advancing projects involving peptide drugs, including Terlipressin, Octreotide, Pucakine, Semaglutide, CT130, CT153, and more.

Our research not only focuses on internal developments but extends to providing technical guidance for various peptide varieties, aiding multiple clients in obtaining regulatory approvals and achieving successful market launches. With a commitment to excellence, our team is at the forefront of advancing peptide-based treatments, contributing to breakthroughs in the realms of metabolic health, infectious diseases, immune disorders, and oncology.

We have established a comprehensive collaborative platform for innovative drug development, encompassing molecular design, target validation, in vitro and in vivo drug screening, CMC (Chemistry, Manufacturing, and Controls) studies, toxicology, pharmacology, and PK/PD (Pharmacokinetics/Pharmacodynamics). Our portfolio includes a series of proprietary key technologies, particularly in the field of sustained modification of peptide drugs, boasting autonomous intellectual property rights.

With a specific focus on GLP-1R and related targets, we have undertaken extensive preclinical research on multiple projects, resulting in significant breakthroughs. Peptide drugs such as CT130 and CT153 cover indications in Type 2 diabetes, cardiovascular risk reduction, weight management, non-alcoholic fatty liver disease, chronic kidney disease, Alzheimer's disease, and more. The pharmacokinetic and pharmacodynamic data for these peptides demonstrate highly promising outcomes, affirming their potential in addressing various medical conditions.